secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001628280-25-032748
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo reports positive Phase 1/2 data for Fabry gene therapy ST-920; BLA plan Q1 2026
--------------------------------------------------------------------------------

- Mean annualized eGFR slope +1.965 at 52 weeks across 32 patients; +1.747 at 104 weeks for 19 patients.
- All 18 patients on ERT at baseline withdrawn from ERT and remain off; α-Gal A activity sustained up to 4.5 years.
- Reported eGFR slope compares favorably to Replagal (-2.2), Fabrazyme (-1.5), Galafold (-0.4) in published studies.
- Significant SF-36 quality-of-life improvements: role-physical +14.8, vitality +9.6, bodily pain +9.0 at week 52.
- No preconditioning required; most adverse events grade 1-2; no safety-related discontinuations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828025032748/0001628280-25-032748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828025032748/sgmo-20250624.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-032748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer